MSN CABAZITAXEL (Accelagen Pty Ltd)
Product name
MSN CABAZITAXEL
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
151 working days (255)
Active ingredients
cabazitaxel
Registration type
New generic medicine
Indication
MSN CABAZITAXEL (concentrated injection vial, diluent vial) in combination with prednisone or prednisolone is indicated for the treatment of patients with metastatic castration resistant prostate cancer previously treated with a docetaxel containing regimen.